GW Pharma cannabis drug gets green light in France
LONDON Oct 21 (Reuters) - GW Pharmaceuticals' cannabis-derived drug Sativex has been recommended for approval in France for the treatment of spasticity due to multiple sclerosis, the drugmaker said on Monday.
Sativex will be sold in France by GW's European partner Almirall following completion of national pricing and reimbursement procedures.
The drug - which is sprayed under the tongue - is currently available in Britain, Spain, Germany, Canada, Denmark, Norway, Israel, Austria, Poland, Sweden, Italy and Finland.
- Nurse defies Ebola quarantine with bike ride; negotiations fail |
- Suspect in Pennsylvania police ambush captured after seven-week manhunt |
- Global shares jump, yen slumps as BOJ cranks up stimulus |
- Oil price declines have small-cap shale investors scrambling
- Japan's central bank shocks markets with more easing as inflation slows